US9587032B2 - IgE antibodies for the inhibition of tumor metastasis - Google Patents

IgE antibodies for the inhibition of tumor metastasis Download PDF

Info

Publication number
US9587032B2
US9587032B2 US13/939,781 US201313939781A US9587032B2 US 9587032 B2 US9587032 B2 US 9587032B2 US 201313939781 A US201313939781 A US 201313939781A US 9587032 B2 US9587032 B2 US 9587032B2
Authority
US
United States
Prior art keywords
tumor
antibody
ige
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/939,781
Other languages
English (en)
Other versions
US20140370001A1 (en
Inventor
Joseph A. Mollick
Pearline Teo
Paul J. Utz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to US13/939,781 priority Critical patent/US9587032B2/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Assigned to THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY reassignment THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UTZ, PAUL J., MOLLICK, JOSEPH A., TEO, Pearline
Priority to CN201480033785.0A priority patent/CN105431205B/zh
Priority to EP14811351.7A priority patent/EP3007773B1/en
Priority to PCT/US2014/042065 priority patent/WO2014201212A1/en
Priority to JP2016519638A priority patent/JP6506745B2/ja
Publication of US20140370001A1 publication Critical patent/US20140370001A1/en
Priority to US15/405,723 priority patent/US10487152B2/en
Publication of US9587032B2 publication Critical patent/US9587032B2/en
Application granted granted Critical
Priority to US16/600,762 priority patent/US11390684B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
US13/939,781 2013-06-12 2013-07-11 IgE antibodies for the inhibition of tumor metastasis Active 2033-08-17 US9587032B2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/939,781 US9587032B2 (en) 2013-06-12 2013-07-11 IgE antibodies for the inhibition of tumor metastasis
JP2016519638A JP6506745B2 (ja) 2013-06-12 2014-06-12 腫瘍転移の阻害用ＩｇＥ抗体
PCT/US2014/042065 WO2014201212A1 (en) 2013-06-12 2014-06-12 IgE ANTIBODIES FOR THE INHIBITION OF TUMOR METASTASIS
EP14811351.7A EP3007773B1 (en) 2013-06-12 2014-06-12 Ige antibodies for the inhibition of tumor metastasis
CN201480033785.0A CN105431205B (zh) 2013-06-12 2014-06-12 抑制肿瘤转移的IgE抗体
US15/405,723 US10487152B2 (en) 2013-06-12 2017-01-13 IgE antibodies for the inhibition of tumor metastasis
US16/600,762 US11390684B2 (en) 2013-06-12 2019-10-14 IgE antibodies for the inhibition of tumor metastasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361834169P 2013-06-12 2013-06-12
US13/939,781 US9587032B2 (en) 2013-06-12 2013-07-11 IgE antibodies for the inhibition of tumor metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/405,723 Continuation US10487152B2 (en) 2013-06-12 2017-01-13 IgE antibodies for the inhibition of tumor metastasis

Publications (2)

Publication Number Publication Date
US20140370001A1 US20140370001A1 (en) 2014-12-18
US9587032B2 true US9587032B2 (en) 2017-03-07

Family

ID=52019400

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/939,781 Active 2033-08-17 US9587032B2 (en) 2013-06-12 2013-07-11 IgE antibodies for the inhibition of tumor metastasis
US15/405,723 Active US10487152B2 (en) 2013-06-12 2017-01-13 IgE antibodies for the inhibition of tumor metastasis
US16/600,762 Active 2034-01-14 US11390684B2 (en) 2013-06-12 2019-10-14 IgE antibodies for the inhibition of tumor metastasis

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/405,723 Active US10487152B2 (en) 2013-06-12 2017-01-13 IgE antibodies for the inhibition of tumor metastasis
US16/600,762 Active 2034-01-14 US11390684B2 (en) 2013-06-12 2019-10-14 IgE antibodies for the inhibition of tumor metastasis

Country Status (5)

Country Link
US (3) US9587032B2 (zh)
EP (1) EP3007773B1 (zh)
JP (1) JP6506745B2 (zh)
CN (1) CN105431205B (zh)
WO (1) WO2014201212A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180002441A1 (en) * 2015-01-15 2018-01-04 Oncoquest, Inc. Methods of increasing delivery of anti-cancer agents to targets

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145022A1 (en) * 2015-03-11 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-dc-hil antibodies for cancer diagnosis, prognosis and therapy
CN108243607A (zh) 2015-09-09 2018-07-03 西雅图儿童医院（Dba西雅图儿童研究所） 用于免疫疗法的巨噬细胞的遗传工程
DE102017125013B4 (de) * 2017-10-25 2019-10-17 Epiontis Gmbh MCC als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere basophiler Granulozyten
US20240101695A1 (en) * 2020-09-01 2024-03-28 The Regents Of The University Of California Immunoglobulin e antibody compositions and methods of use
CN112684175B (zh) * 2021-01-23 2021-09-24 上海科语生物科技有限公司 一种检测卵巢癌的试剂盒
WO2023023871A1 (en) * 2021-08-27 2023-03-02 Canariabio Inc. Combination of an ige monoclonal antibody specific to a cancer antigen and nk cell for the treatment of cancer

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050118651A1 (en) 2003-05-30 2005-06-02 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20060292643A1 (en) 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours
US20090136520A1 (en) * 2005-08-22 2009-05-28 Kufe Donald W Mitochondrial localization of muc1
US20100098683A1 (en) * 2006-12-08 2010-04-22 Dana-Farber Cancer Institute, Inc. MUC1 and Galectin-3
US20100105873A1 (en) * 2005-07-01 2010-04-29 Medimmune, Inc. Integrated approach for generating multidomain protein therapeutics
US20110021755A1 (en) * 2003-03-03 2011-01-27 Xencor, Inc. Optimized Fc Variants
US20120040375A1 (en) * 2008-10-28 2012-02-16 National University Corporation Hokkaido University Anti-muc1 antibody
US20120258119A1 (en) 2009-10-02 2012-10-11 Christoph Renner Anti-fibroblast activation protein antibodies and methods and uses thereof
US20130022614A1 (en) 2008-04-09 2013-01-24 The Regents Of The University Of California IgE ANTIBODIES FOR THE TREATMENT OF CANCER
US20130034557A1 (en) 2010-04-19 2013-02-07 Ezose Sciences, Inc. Cancer-Related Glycopeptide Epitopes, Antibodies And Methods Of Use
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292643A1 (en) 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours
US20110021755A1 (en) * 2003-03-03 2011-01-27 Xencor, Inc. Optimized Fc Variants
US20050118651A1 (en) 2003-05-30 2005-06-02 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20100105873A1 (en) * 2005-07-01 2010-04-29 Medimmune, Inc. Integrated approach for generating multidomain protein therapeutics
US20090136520A1 (en) * 2005-08-22 2009-05-28 Kufe Donald W Mitochondrial localization of muc1
US20100098683A1 (en) * 2006-12-08 2010-04-22 Dana-Farber Cancer Institute, Inc. MUC1 and Galectin-3
US20130022614A1 (en) 2008-04-09 2013-01-24 The Regents Of The University Of California IgE ANTIBODIES FOR THE TREATMENT OF CANCER
US20120040375A1 (en) * 2008-10-28 2012-02-16 National University Corporation Hokkaido University Anti-muc1 antibody
US20120258119A1 (en) 2009-10-02 2012-10-11 Christoph Renner Anti-fibroblast activation protein antibodies and methods and uses thereof
US20130034557A1 (en) 2010-04-19 2013-02-07 Ezose Sciences, Inc. Cancer-Related Glycopeptide Epitopes, Antibodies And Methods Of Use
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
Coussens, L. M., et al., "Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?" Science, 339: 286-291 (2013).
Dalton, D. K., et al., "The roles of mast cells in anticancer immunity," Cancer Immunol. Immunother. (2012).
Daniels et al.; "The IgE Antibody and Its Use in Cancer Immunotherapy", Humana Press, XP008179200, Cancer and IgE, Introducing the Concept of AllergoOncology, Chapter 7, Springer Science+Business Media, LLC 2010, p. 159-183.
Daniels, T. R., et al., "Animal models for IgE-meditated cancer immunotherapy," Cancer Immunol. Immunother. (2011).
Daniels, T. R., et al., "Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells," Cancer Immunol. Immunother. (2011).
Danussi et al.: "A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction", Glycobiology, vol. 19, No. 10, pp. 1056-1067, 2009.
Extended European Search Report No. EP 14811351.7, May 9, 2016.
Homayounfar et al.; "Multimodal treatment options for bilobar colorectal liver metastases", Langenbecks Arch. Surg. (2010) 395:633-641.
Jiang et al. (J. Biol. Chem., 280: 4656-4662, 2005). *
Karagiannis et al.; "IgE Interacts with Potent Effector Cells Against Tumors: ADCC and ADCP", Humana Press, Cancer and IgE, Introducing the Concepts of AllergoOncology, Chapter 8, Springer Science+Business Media, LLC 2010, pp. 185-213.
Karagiannis, P. et al., "Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells," Cancer Immunol. Immunother., 58: 915-930 (2009).
Karagiannis, S. N., et al., "Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells," Cancer Immunol. Immunother., 57: 247-263 (2008).
Muthuswamy, R., et al., "NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of chemokine microenvironment to enhance the recruitment of cytolytic T effector cells," Cancer Res. in Press (2012).
Muthuswamy, R., et al., "NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of chemokine microenvironment to enhance the recruitment of cytolytic T effector cells," Cancer Res. in Press (2012).
Rudman, S. M., et al., "Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcepsilonRI-mediated basophil activation by a tumourspecific IgE antibody to evaluate the risk of type I hypersensitivity," Clinical & Experimental Allergy, 41, 1400-1413 (2011).
Rudman, S. M., et al., "Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcεRI-mediated basophil activation by a tumourspecific IgE antibody to evaluate the risk of type I hypersensitivity," Clinical & Experimental Allergy, 41, 1400-1413 (2011).
Spillner, E., et al., "Recombinant IgE antibody engineering to target EGFR," Cancer Immunol. Immunother., 61: 1565-1573 (2012).
Stancovski et al. (PNAS, 88: 8691-8695, 1991). *
Teo, P. Z., et al., "Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1," Cancer Immunol. Immunother. (2012).
Toh, B., et al., "Myeloid cells Prime drivers of tumor progression," Oncolmmunology, 1(8): 1360-1367; Nov. 2012.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180002441A1 (en) * 2015-01-15 2018-01-04 Oncoquest, Inc. Methods of increasing delivery of anti-cancer agents to targets
US10975163B2 (en) * 2015-01-15 2021-04-13 Oncoquest Pharmaceuticals Inc. Methods of increasing delivery of anti-cancer agents to targets

Also Published As

Publication number Publication date
WO2014201212A1 (en) 2014-12-18
JP6506745B2 (ja) 2019-04-24
US20170129965A1 (en) 2017-05-11
CN105431205A (zh) 2016-03-23
US11390684B2 (en) 2022-07-19
JP2016521750A (ja) 2016-07-25
US20140370001A1 (en) 2014-12-18
US10487152B2 (en) 2019-11-26
EP3007773A1 (en) 2016-04-20
EP3007773A4 (en) 2016-06-08
EP3007773B1 (en) 2019-03-27
CN105431205B (zh) 2020-07-07
US20200087413A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
US11390684B2 (en) IgE antibodies for the inhibition of tumor metastasis
JP7203446B2 (ja) Ｔｉｇｉｔ結合物質およびその使用法
US20210403553A1 (en) Combination therapy for treatment of disease
JP7133241B2 (ja) Ｉｆｎと抗ｐｄ－ｌ１抗体の融合タンパク質およびその使用
CA3034912A1 (en) Il-15 variants and uses thereof
KR20170108073A (ko) Tnfrsf-결합제 및 이의 용도
CA2957531A1 (en) Sirp alpha-antibody fusion proteins
WO2021000530A1 (zh) 一种双特异性抗体及其制备方法与应用
JP7148406B2 (ja) 免疫チェックポイントモジュレーターとのｔ細胞リダイレクティング多機能抗体の組み合わせとその使用
JP2023502091A (ja) 免疫療法のための組成物及び方法
CA3146474A1 (en) Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents
US20220177599A1 (en) Dual chimeric antigen receptor targeting epcam and icam-1
US20220389104A1 (en) Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
RU2812481C2 (ru) Вовлекающие nk молекулы и способы их применения
WO2023098785A1 (zh) 抗4-1bb抗体及其用途
Cappuzzello A DONOR-DEPENDENT SUBSET OF CYTOKINE-INDUCED KILLER (CIK) CELLS EXPRESS CD16 AND CAN BE RETARGETED TO EXERT A POTENT ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)
JP2013519689A (ja) 慢性炎症状態の治療
Hess Targeted delivery of immunomodulatory proteins: evaluation of novel antibody-chemokine and antibody-cytokine fusion proteins for cancer therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY;REEL/FRAME:031693/0954

Effective date: 20131120

AS Assignment

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOLLICK, JOSEPH A.;TEO, PEARLINE;UTZ, PAUL J.;SIGNING DATES FROM 20131008 TO 20131211;REEL/FRAME:031971/0353

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4